Abstract:Noncovalent interactions between small-molecule drugs and protein targets assume a pivotal role in drug design. Moreover, the design of covalent inhibitors, forming covalent bonds with amino acid residues, requires rational reactivity for their covalent warheads, presenting a key challenge as well. Understanding the intricacies of these interactions provides a more comprehensive understanding of molecular binding mechanisms, thereby guiding the rational design of potent inhibitors. In this study, we adopted the fragment-based drug design approach, introducing a novel methodology to extract noncovalent and covalent fragments according to distinct three-dimensional (3D) interaction modes from noncovalent and covalent compound libraries. Additionally, we systematically replaced existing ligands with rational fragment substitutions, based on the spatial orientation of fragments in 3D space. Furthermore, we adopted a molecular generation approach to create innovative covalent inhibitors. This process resulted in the recombination of a noncovalent compound library and several covalent compound libraries, constructed by two commonly encountered covalent amino acids: cysteine and serine. We utilized noncovalent ligands in KLIFS and covalent ligands in CovBinderInPDB as examples to recombine noncovalent and covalent libraries. These recombined compound libraries cover a substantial portion of the chemical space present in the original compound libraries and exhibit superior performance in terms of molecular scaffold diversity compared to the original compound libraries and other 11 commercial libraries. We also recombined BTK-focused libraries, and 23 compounds within our libraries have been validated by former researchers to possess potential biological activity. The establishment of these compound libraries provides valuable resources for virtual screening of covalent and noncovalent drugs targeting similar molecular targets.

Advanced technologies for screening and identifying covalent inhibitors

Advances in covalent drug discovery

Covalent Inhibition in Drug Discovery

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Recent applications of covalent chemistries in protein-protein interaction inhibitors

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors

CovalentInDB 2.0: an Updated Comprehensive Database for Structure-Based and Ligand-Based Covalent Inhibitor Design and Screening.

Identification of highly selective covalent inhibitors by phage display

Applications of covalent chemistry in targeted protein degradation

Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

Covalent fragment-based drug discovery for target tractability

Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation

Covalent hits and where to find them

Covalent inhibitors meet epigenetics: New opportunities

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Constructing Innovative Covalent and Noncovalent Compound Libraries: Insights from 3D Protein–Ligand Interactions

Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery

Discover Novel Covalent Inhibitors Targeting FLT3 Through Hybrid Virtual Screening Strategy.